ONCY Key Statistics, Chart & Performance
The current stock price of ONCY is 1 USD. In the past month the price decreased by -16.67%. In the past year, price increased by 4.81%.
ONCY Latest News, Press Relases and Analysis
ONCY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About ONCY
Company Profile
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2001-10-05. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Company Info
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 28
Phone: 14036707377
ONCOLYTICS BIOTECH INC / ONCY FAQ
Can you describe the business of ONCOLYTICS BIOTECH INC?
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2001-10-05. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Can you provide the latest stock price for ONCOLYTICS BIOTECH INC?
The current stock price of ONCY is 1 USD. The price increased by 0.86% in the last trading session.
Does ONCOLYTICS BIOTECH INC pay dividends?
ONCY does not pay a dividend.
How is the ChartMill rating for ONCOLYTICS BIOTECH INC?
ONCY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for ONCOLYTICS BIOTECH INC?
ONCOLYTICS BIOTECH INC (ONCY) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ONCY stock?
ONCOLYTICS BIOTECH INC (ONCY) has a market capitalization of 97.41M USD. This makes ONCY a Micro Cap stock.
ONCY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ONCY. When comparing the yearly performance of all stocks, ONCY turns out to be only a medium performer in the overall market: it outperformed 59.81% of all stocks.
ONCY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ONCY. Both the profitability and financial health of ONCY have multiple concerns.
ONCY Financial Highlights
Over the last trailing twelve months ONCY reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS decreased by -8.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.26% | ||
| ROE | -499.46% | ||
| Debt/Equity | 0.1 |
ONCY Forecast & Estimates
8 analysts have analysed ONCY and the average price target is 3.32 USD. This implies a price increase of 231.94% is expected in the next year compared to the current price of 1.